Targets › TCRA
4 programs from 4 companies in 7 trials: 4 Phase 1, 3 Phase 2; Oncology, Hematology, Metabolic and endocrine; next expected readout Jan 2027.
Constant region of T cell receptor (TR) alpha chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01848)
Open in Phaseline: the race on TCRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) Selective depletion of T cells expressing TCR alpha/beta to reduce graft-versus-host disea | TCRA, TCRB | Phase 2 | Fanconi Anemia | Jan 2027 |
| Johns Hopkins All Children's Hospital | TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan | TCRA, TCRB, CD19 | Phase 2 | Hemoglobinopathy (Disorder); Primary Immune Deficiency Disorders | Jun 2027 |
| Marengo Therapeutics | STAR0602 Selective TCR-targeting bifunctional antibody-fusion molecule | TCRA, TCRB | Phase 1 | Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid Tumors | Jan 2027 |
| Chinese PLA General Hospital | TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge | TRBC, SPPL3, CD19, TCRA | Phase 1 | Acute Lymphocytic Leukemia; Non-hodgkin Lymphoma | Feb 2027 |
Acute Lymphocytic Leukemia (1) Non-hodgkin Lymphoma (1) Hemoglobinopathy (Disorder) (1) Primary Immune Deficiency Disorders (1) Fanconi Anemia (1) Triple Negative Locally Advanced Non-resectable Breast Cancer (1) Advanced Solid Tumors (1)
mixed (2), other (1), small molecule (1)
Chinese PLA General Hospital (1) Johns Hopkins All Children's Hospital (1) Masonic Cancer Center, University of Minnesota (1) Marengo Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.